OBJECTIVE—Diabetes increases the risk of coronary heart disease (CHD) to a greater extent in women than in men. We investigated whether type 1 diabetic patients with short duration of disease and without complications have an altered oxidative status and whether there are differences between men and women.

RESEARCH DESIGN AND METHODS—We investigated oxidative status in 29 control subjects and 37 patients with uncomplicated type 1 diabetes with duration of 6 ± 3 years.

RESULTS—Compared with control subjects, type 1 diabetic patients had lower total plasma antioxidant capacity (TRAP) (720.3 ± 111.2 vs. 972.5 ± 97.7 μmol/l in men, P < 0.001; 579.8 ± 95.4 vs. 930.1 ± 84.2 in women, P < 0.001), higher lipid hydroperoxide (ROOH) levels (6.4 ± 2.2 vs. 2.0 ± 0.7 μmol/l in men, P < 0.001; 8.1 ± 1.9 vs. 2.2 ± 0.6 in women, P < 0.001), higher total conjugated diene (CD) levels (0.037 ± 0.003 vs. 0.033 ± 0.002 A.U. in men, P < 0.001), lower 246-nm CD levels (0.0032.± 0.0010 vs. 0.0070 ± 0.0012 A.U. in men, P < 0.001; 0.0022 ± 0.0011 vs. 0.0072 ± 0.0014 A.U. in women, P < 0.001), and higher 232-nm CD levels (0.0348 ± 0.0041 vs. 0.0257 ± 0.0022 A.U. in men, P < 0.001; 0.0346 ± 0.0031 vs. 0.0246 ± 0.0074 A.U. in women, P < 0.001). Compared with diabetic men, diabetic women had lower TRAP (P < 0.01), higher ROOH levels (P < 0.01), and lower 246-nm CD levels (P < 0.05). Plasma concentration of uric acid was significantly lower in patients with type 1 diabetes than in control subjects (3.3 ± 0.3 vs. 4.3 ± 0.2 mg/dl; P = 0.009) with a significant difference between women and men with type 1 diabetes (2.6 ± 0.3 vs. 3.9 ± 0.3, respectively; P = 0.009).

CONCLUSIONS—Our findings suggest that reduced antioxidant activity and increased oxidative stress occur early after the diagnosis of type 1 diabetes, especially in women, and this might explain, at least in part, the increased susceptibility of diabetic women to cardiovascular complications.

Diabetes is a significant risk factor for macrovascular disease, and diabetic patients have a greater risk of cardiovascular mortality compared with the general population (1,2). Diabetes reduces the gender protection against vascular disease in premenopausal women, and in diabetic women, the coronary heart disease (CHD) mortality rate is significantly higher than in nondiabetic women (35). Moreover, several studies show that diabetes increases cardiovascular risk to a greater extent in women than in men (6,7). There is currently great interest in the potential role of increased oxidative stress in the development of diabetic complications (8,9). In patients with diabetes, oxidative stress seems to be caused by both increased production of plasma reactive oxygen species and reduction of antioxidant defenses (10), with a consequent increase in lipid peroxidation (11,12) and oxidized LDLs, which are more atherogenic than native LDLs (13). Some authors observed increased oxidative stress in early stages of type 1 diabetes in children and adolescents (14)

Recently, we demonstrated in patients with well-controlled type 1 diabetes that total plasma antioxidant capacity (TRAP) was significantly lower and that two different markers of lipid peroxidation, such as conjugated dienes (CDs) and lipid hydroperoxides (ROOHs), were significantly augmented (15). The aim of our study was to investigate whether type 1 diabetic patients with short duration of disease and without diabetic complications have altered oxidative status, and whether there is any difference in the parameters of oxidative damage between men and women in order to better understand the increased risk of CHD in the diabetic women.

We studied 37 patients with type 1 diabetes of short duration (19 men, 18 women) who were attending the Diabetic Outpatient Clinic of the Catholic University School of Medicine, and 29 control subjects (15 men, 14 women) who were comparable for age, gender, smoking habit, diet, and physical activity. Patients were included in the study only if their duration of disease was <10 years and if they had no history of diabetic complications, such as nephropathy, neuropathy, hypertension, cardiac ischemic disease, and peripheral vasculopathy, according to the criteria of the EURODIAB IDDM Complications Study (16), as reported in detail in a previous study (15). Further exclusion criteria included administration of drugs other than insulin (such as antihypertensive agents, aspirin, or vitamin supplements), history of smoking, pregnancy, and current illness (such as hepatic, cardiac, or renal disease). Neither diabetic nor control women were on estroprogestinic therapy. The characteristics of the study population are shown in Table 1.

Blood sampling

Venous blood samples were collected after 12-h overnight fasting only from patients in whom values of glycemia were <125 mg/dl that morning. The samples were collected in sampling vials containing heparin for preparation of plasma. Plasma samples were stored under nitrogen at −80°C and used within 1 month for analysis of TRAP and measurement of CD and ROOH.

Measurement of TRAP

As previously reported (15,17), the assay is based on the quenching of the 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical cation (ABTS · +) by antioxidants contained in the sample. The ABTS · + formation was monitored continuously as an increased absorbance at 734 nm, at 20°C. The delay or inhibition time between the addition of H2O2 (time 0) and the onset of increased absorbance (ABTS · + formation) was measured. The assay was standardized using a water-soluble vitamin E analog (Trolox). Intra and interassay coefficients of variation for this method were 6.2 and 8.5%, respectively.

Measurement of lipid peroxidation products

Plasma lipids were extracted by a modification of the method of Folch, as previously described (15,18).

CDs

As previously reported, CDs were measured by second-derivative spectrophotometry (15,19), which allows great sensitivity, because the CD shoulder that appears in the ordinary spectrum translates into sharp minima peaks, which are more easily measurable. Furthermore, this technique permits a discrimination between the different CD structures (e.g., cis-trans and trans-trans conformation) present in the sample (20). Minima at 232 and 246 nm were ascribed to the trans-trans and cis-trans CD isomers, respectively (21,22). These minima were quantified in arbitrary units as d2A/dλ2. The CD ratio measurement at 246- and 232-nm minima of the derivative spectra, which can provide an indirect evaluation of plasma antioxidant capacity, was then calculated (19,20). Intra- and interassay coefficients of variation for this method were 8.2 and 11.4%, respectively.

ROOHs

As reported elsewhere (15), plasma ROOH content was determined with the FOX 2 assay for lipids (23,24). ROOH content in plasma samples was determined as a function of the mean absorbance difference of samples with and without elimination of ROOH by triphenylphosphine (TPP). Intra- and interassay coefficients of variation for this method were 6.5 and 8.3%, respectively.

Statistical analysis

Statistical calculations were performed using StatView software (version 4.01; SAS Institute, Cary, NC). Values are given as means ± SD. Comparisons between diabetic and control groups and within individual groups were made using ANOVA and Scheffe’s F test for multiple comparisons. Simple linear regression analysis was used to detect relationships among TRAP values, 246-nm CD, ROOH, and plasma HbA1c as the independent variable.

As shown in Table 2, compared with control subjects, type 1 diabetic patients had significantly lower TRAP values, significantly higher ROOH levels, increased total CD levels (only in men), significantly lower 246-nm CD levels, and significantly augmented 232-nm CD levels. In type 1 diabetic patients of both sexes, the CD isomer ratio was directly correlated with TRAP (R = 0.468, P < 0.02) and inversely correlated with ROOH (R = −0.486, P = 0.003) (Fig. 1). No significant differences were found between patients with type 1 diabetes and control subjects in the concentration of total, HDL, and LDL cholesterol and triglycerides; in age; and in BMI.

As shown in Table 2, compared with diabetic men, women with type 1 diabetes had significantly higher ROOH levels, significant lower TRAP values, and significantly lower 246-nm CD levels, but there were no significant differences in total and 232-nm CD levels. No significant differences were found between men and women with type 1 diabetes in concentration of total, HDL, and LDL cholesterol and triglycerides, age, BMI, and insulin dosage.

As shown in Table 1, uric acid levels were significantly lower in type 1 diabetic patients than in control subjects, both in men with type 1 diabetes compared with male control subjects and in women with type 1 diabetes compared with female control subjects. Moreover, there was a significant difference between women and men with type 1 diabetes.

In type 1 diabetic patients, uric acid levels were directly correlated with TRAP (R = 0.484, P = 0.02) and inversely correlated with ROOH (R = −0.449, P = 0.03).

In a simple linear regression analysis between HbA1c as the independent variable and TRAP, ROOH, and 246-nm CD, we did not find any significant relationship in type 1 diabetic patients.

In this study, we investigated whether oxidative stress occurs early during the course of disease in type 1 diabetic patients without diabetic complications, and whether any difference exists between diabetic men and women in this regard.

Compared with control subjects, our type 1 diabetic patients had significantly lower TRAP and 246-nm CD levels and significantly higher ROOH, 232-nm CD, and total CD levels, at least in men (Table 2). Therefore, diabetic patients have an early impairment of plasma antioxidant capacity and increased oxidative stress, even in the early stages of the disease. These data are in agreement with those of other authors (14), although they studied the oxidative stress by evaluating the enzymatic activity of superoxide dismutase and glutathione peroxidase in children and adolescents.

The decrease in 246-nm CD and the increase in 232-nm CD, expression of a decreased CD isomer ratio, are indicative of a large depletion of antioxidants in type 1 diabetic patients, because in physiological conditions, oxidative reactions are directed toward the formation of cis-trans CDs. In type 1 diabetes, the hydrogen-donating ability of plasma, as measured by TRAP, is decreased because of the consumption of antioxidants and because the kinetic equilibrium of the oxidation process is shifted toward trans-trans products, with an increase of the 232-nm CD. Interestingly, in our patients, the CD isomer ratio was positively correlated with TRAP and inversely correlated with ROOH, as shown in Fig. 1.

Our reported increase in plasma lipid ROOHs and CDs was not due to an increase in the content of circulating lipids, because there were no significant differences in the plasma lipid levels between normal and diabetic subjects.

We did not find any relationship between metabolic control, as evaluated by HbA1c, antioxidant status, and markers of oxidative stress. This can be explained by the fact that HbA1c is a “mean” evaluation of glycemic control and reflects, only in part, glycemic fluctuations, such as postprandial hyperglycemia or disglycemia states, which may induce a pro-oxidative status and may play a significant role in the pathogenesis of diabetic complications (10,11,25). In fact, a recent prospective study by Berg et al. (26) showed that intensive insulin treatment can reduce the increased ROOH levels in type 1 diabetic patients. Moreover, recent epidemiological studies (27) suggest that HbA1c is related to total mortality in the general population, determining an increased risk even for values >5%.

Data from epidemiological surveys have shown a significant decrease of uric acid levels after the onset of type 1 diabetes (28). Uric acid has been proposed to play a pivotal role in the antioxidant defense systems in humans (2931). The intriguing question of a role for uric acid in the free radical–scavenging processes in diabetes has received little attention. Elevated glucose levels seem to be the principal mechanism, because hyperglycemia has, at least in part, an osmotic diuretic effect, leading to an excessive excretion of uric acid (32). Some authors reported that even in type 1 diabetic patients with good metabolic control, plasma uric acid levels are not completely normalized (33), possibly because of the glomerular hyperfiltration that characterizes the first years of type 1 diabetes, and can contribute to the hyperuricosuria and hypouricemia found in type 1 diabetic patients (34).

In our study, we report not only decreased levels of uric acid in type 1 diabetic patients compared with control subjects but also, for the first time, a more evident decrease in uric acid levels in diabetic women compared with diabetic men. This fact, together with the positive relationship found between uric acid levels and antioxidant capacity, as shown in Fig. 1, confirms the importance of uric acid for the antioxidant defenses (35).

Many studies have shown that the protective effect of female gender against cardiovascular risk is lost in the presence of diabetes (5) and that the increased relative risk for CHD in diabetic women is independent from the conventional risk factors (34). Moreover, it has been reported recently that in diabetic women, coronary artery calcification, a measure of atherosclerotic plaque burden, is greatly increased and the gender difference is lost (36). Because little of this can be explained by known coronary risk factors, the observed increase in lipid ROOH along with the decrease in TRAP and uric acid levels in diabetic women compared with diabetic men could play an important role in the development of the atherosclerotic plaque and may represent one of the pathophysiological explanations for the higher cardiovascular risk of diabetic versus nondiabetic women (36,37).

Many studies support the role of estrogens in the primary and secondary prevention of CHD among women (38,39), particularly in normalizing blood lipids or inducing endothelium-dependent vasodilation stimulating nitric oxide synthetase (4042). It has recently been demonstrated in premenopausal diabetic women that there is a decreased estrogen-inducing endothelium-dependent vasodilation (43), which can explain the increased risk of cardiovascular mortality in diabetic women. It could be possible that the augmented oxidative stress in diabetic women induced by hyperglycemic events, not detectable by HbA1c values, could impair the estrogen protective effect on lipoprotein oxidizability (44,45) and/or on endothelium-dependent vasodilation (46).

In conclusion, our data suggest that type 1 diabetic patients with a short duration of disease and good metabolic control show an early imbalance in their antioxidant capacity and augmented levels of lipid ROOH and CD, even in the absence of complications. Reduced uric acid levels seem to contribute to this phenomenon, especially in diabetic women. Diabetic women show, independently from other factors, a decreased antioxidant capacity and an increased rate of lipoperoxidation compared with diabetic men. The severe alteration of the oxidative pattern in diabetic women may offer one possible pathogenetic explanation for the higher incidence of cardiovascular complications observed in diabetic versus nondiabetic women.

Further studies are needed to investigate a possible effect of hyperglycemia and oxidative stress on the hormonal pattern and/or activity in women with type 1 diabetes.

Figure 1—

Relation between CD isomer ratio and TRAP (A) (R = 0.468, P = 0.02) or ROOH (B) (R = −0.486, P = 0.03) in patients with type 1 diabetes.

Figure 1—

Relation between CD isomer ratio and TRAP (A) (R = 0.468, P = 0.02) or ROOH (B) (R = −0.486, P = 0.03) in patients with type 1 diabetes.

Close modal
Table 1—

Baseline characteristics of diabetic and control subjects

Type 1 diabetes (women)Type 1 diabetes (men)Overall type 1 diabetesControl subjects (women)Control subjects (men)Overall control subjects
Age (years) 31.3 ± 8.4 31.6 ± 9.3 30 ± 8.2 31.3 ± 8.4 31.6 ± 9.3 31.5 ± 8.2 
Duration of disease (years) 6.8 ± 2.7 5.6 ± 2.9 6 ± 3 — — — 
HbA1c (%) 7.3 ± 0.8 7.4 ± 1.3 7.4 ± 1.1 — — — 
BMI (kg/m223.5 ± 3.2 24.0 ± 2.0 23.6 ± 2.8 23.3 ± 4.1 25.6 ± 1.7 23.7 ± 3.4 
Cholesterol (mg/dl) 195 ± 38.8 189 ± 37 193 ± 34 189 ± 39.4 191.6 ± 33.9 190.3 ± 35.6 
Triglycerides (mg/dl) 87.2 ± 30.6 83.9 ± 34.4 86 ± 33.1 80.4 ± 33.5 91.5 ± 31.1 85.9 ± 31.9 
HDL cholesterol (mg/dl) 57.1 ± 9.5 57.6 ± 8.3 57 ± 9 55.2 ± 8.9 57.6 ± 6.6 56.6 ± 7.3 
LDL cholesterol (mg/dl) 116 ± 32 120 ± 26 119 ± 29 118 ± 29 123 ± 34 121 ± 32 
Uric acid (mg/dl) 2.6 ± 0.3* 3.9 ± 0.3 3.3 ± 0.3 4.0 ± 0.2 4.5 ± 0.2 4.3 ± 0.2 
Systolic blood pressure (mmHg) 116 ± 12 118 ± 11 117 ± 11 117 ± 13 116 ± 10 116 ± 11 
Diastolic blood pressure (mmHg) 74 ± 13 75 ± 10 74 ± 12 72 ± 11 76 ± 12 74 ± 11 
Type 1 diabetes (women)Type 1 diabetes (men)Overall type 1 diabetesControl subjects (women)Control subjects (men)Overall control subjects
Age (years) 31.3 ± 8.4 31.6 ± 9.3 30 ± 8.2 31.3 ± 8.4 31.6 ± 9.3 31.5 ± 8.2 
Duration of disease (years) 6.8 ± 2.7 5.6 ± 2.9 6 ± 3 — — — 
HbA1c (%) 7.3 ± 0.8 7.4 ± 1.3 7.4 ± 1.1 — — — 
BMI (kg/m223.5 ± 3.2 24.0 ± 2.0 23.6 ± 2.8 23.3 ± 4.1 25.6 ± 1.7 23.7 ± 3.4 
Cholesterol (mg/dl) 195 ± 38.8 189 ± 37 193 ± 34 189 ± 39.4 191.6 ± 33.9 190.3 ± 35.6 
Triglycerides (mg/dl) 87.2 ± 30.6 83.9 ± 34.4 86 ± 33.1 80.4 ± 33.5 91.5 ± 31.1 85.9 ± 31.9 
HDL cholesterol (mg/dl) 57.1 ± 9.5 57.6 ± 8.3 57 ± 9 55.2 ± 8.9 57.6 ± 6.6 56.6 ± 7.3 
LDL cholesterol (mg/dl) 116 ± 32 120 ± 26 119 ± 29 118 ± 29 123 ± 34 121 ± 32 
Uric acid (mg/dl) 2.6 ± 0.3* 3.9 ± 0.3 3.3 ± 0.3 4.0 ± 0.2 4.5 ± 0.2 4.3 ± 0.2 
Systolic blood pressure (mmHg) 116 ± 12 118 ± 11 117 ± 11 117 ± 13 116 ± 10 116 ± 11 
Diastolic blood pressure (mmHg) 74 ± 13 75 ± 10 74 ± 12 72 ± 11 76 ± 12 74 ± 11 

Data are means ± SD.

*

P < 0.01 for men with type 1 diabetes versus control men and women with type 1 diabetes versus control women;

P < 0.009 for women with type 1 diabetes versus men with type 1 diabetes;

P < 0.009 for type 1 diabetes versus control subjects.

Table 2—

Antioxidant status and lipoperoxide levels in the normal men and normal women, men with type 1 diabetes, and women with type 1 diabetes

Total CD246-nm CD232-nm CDTRAPROOH
Normal men 0.033 ± 0.002 0.0070 ± 0.0012 0.0257 ± 0.0022 972.5 ± 97.7 2.0 ± 0.7 
Normal women 0.032 ± 0.003 0.0072 ± 0.0014 0.0246 ± 0.0074 930.1 ± 84.2 2.2 ± 0.6 
Diabetic men 0.037 ± 0.003* 0.0032 ± 0.0010* 0.0348 ± 0.0041* 720.3 ± 111.2* 6.4 ± 2.2* 
Diabetic women 0.036 ± 0.003 0.0022 ± 0.0011 0.0346 ± 0.003 579.8 ± 95.4§ 8.1 ± 1.9§ 
ANOVA F value (df3,62) 11.46 81,81 25,78 60.43 76.55 
Total CD246-nm CD232-nm CDTRAPROOH
Normal men 0.033 ± 0.002 0.0070 ± 0.0012 0.0257 ± 0.0022 972.5 ± 97.7 2.0 ± 0.7 
Normal women 0.032 ± 0.003 0.0072 ± 0.0014 0.0246 ± 0.0074 930.1 ± 84.2 2.2 ± 0.6 
Diabetic men 0.037 ± 0.003* 0.0032 ± 0.0010* 0.0348 ± 0.0041* 720.3 ± 111.2* 6.4 ± 2.2* 
Diabetic women 0.036 ± 0.003 0.0022 ± 0.0011 0.0346 ± 0.003 579.8 ± 95.4§ 8.1 ± 1.9§ 
ANOVA F value (df3,62) 11.46 81,81 25,78 60.43 76.55 

Data are means ± SD. Analyses of variance and Scheffe’s F test were used for multiple comparisons.

*

P < 0.001 versus normal men;

P < 0.05 versus type 1 diabetic men;

P < 0.001 versus normal women;

§

P < 0.01 versus type 1 diabetic men;

P < 0.001.

This work was supported by a MURST ‘97 grant “Prediction, prevention and intervention in diabetes mellitus and its complications.”

We thank Dr. Paolo Magnani for special revision of the English language in the manuscript. This paper is dedicated to Patrizia Cotroneo.

1
Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr.
Diabetes
36
:
523
–534,
1987
2
Haffner SM, Letho S, Ronnamaa T, Pyorala K, Laakso M: Coronary heart disease mortality in subjects with type 2 diabetes and in non diabetic subjects with and without previous myocardial infarction.
N Engl J Med
339
:
229
–234,
1998
3
Laing SP, Swedlow AJ, Slater DS, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC. Qiao Z, Keen H: The British Diabetic Association Cohort Study II: cause specific mortality in patients with insulin-treated diabetes mellitus.
Diabet Med
16
:
466
–471,
1999
4
Krolewski AS, Kosinnski EJ, Warram JI, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR: The Magnitude and determinants of coronary artery disease in juvenile-onset insulin dependent diabetes.
Am J Cardiol
59
:
750
–755,
1987
5
Kannel WB, Wilson PWF: Rish factors that attenuate the female coronary advance.
Arch Intern Med
155
:
57
–61,
1995
6
Heyden S, Heiss G, Bartel AG, Hames CG: Sex differences in coronary mortality among diabetics in Evans County, Georgia.
J Chron Dis
33
:
265
–273,
1980
7
Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults.
JAMA
281
:
1291
–1297,
1999
8
Wolff SP: The potential role of oxidative stress in diabetes and its complications: novel implications for theory and therapy. In
Diabetic Complications: Scientific and Clinical Aspects
. Crabbe MJC, Ed. New York, Churchill-Livingston,
1987
, p.
167
–220
9
Baynes JW: Role of oxidative stress in development of complications in diabetes.
Diabetes
40
:
405
–412,
1991
10
Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications.
Diabetes Care
19
:
257
–267,
1996
11
Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B, Betteridge DJ: Relationships between plasma measures of oxidative stress and metabolic control in non-insulin dependent diabetes mellitus.
Diabetologia
40
:
647
–653,
1997
12
Haffner SM, Agil A, Mykkanen L, Stern MP, Jialal L: Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM.
Diabetes Care
18
:
646
–652,
1995
13
Wiztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis.
J Clin Invest
88
:
1785
–1792,
1991
14
Dominguez C, Ruiz E, Gussinye M, Carrascosa A: Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents.
Diabetes Care
21
:
1736
–1742,
1998
15
Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G: Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM.
Diabetes
46
:
1853
–1858,
1997
16
Stephensen J, Fuller JH for the EURODIAB Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.
Diabetologia
37
:
278
–285,
1994
17
Rice-Evans C, Miller NJ: Total antioxidant status in plasma and body fluids.
Methods Enzymol
234
:
279
–293,
1994;
18
Folch J, Lees M, Sloane Stanley GH: A simple method for isolation and purification of total lipids from animal tissues.
J Biol Chem
226
:
497
–509,
1957
19
Corongiu FP, Banni S: Detection of conjugated dienes by second derivative ultraviolet spectrophotometry.
Methods Enzymol
233
:
303
–310,
1994
20
Sergent O, Morel I, Cogrel P, Chevanne M, Pasdeloup N, Brissot P, Lescoat G, Cillard P, Cillard J: Simultaneous measurements of conjugated dienes and free malondialdehyde, used as micromethod for evaluation of lipid proxidation in rat hepatocyte cultures.
Chem Phys Lipids
65
:
133
–139,
1993
21
O’Haver TC: Potential clinical applications of derivative and wavelength-modulation spectrometry.
Clin Chem
25
:
1548
–1553,
1979
22
Situnayake RD, Crump BJ, Zezulka AV, Davis M, McConkey B, Thurnham DI: Measurement of conjugated diene lipids by derivative spectroscopy in heptane extracts of plasma.
Ann Clin Biochem
27
:
258
–266,
1990
23
Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP: Measurement of plasma hydroperoxide concentrations by the ferrous oxidatio-xylenol orange assay in conjunction with triphenylphosphine.
Anal Biochem
220
:
403
–409,
1994
24
Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP: Elevated levels of authentic plasma hydroperoxides in NIDDM.
Diabetes
44
:
1054
–1058,
1995
25
Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 diabetic patients.
Diabetes Care
21
:
1529
–1533,
1998
26
Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler H, Bangstad HJ, Hanssen KF: Hydroperoxides in plasma are reduced by intensified insulin treatment.
Diabetes Care
21
:
1295
–1298,
1998
27
Khaw K-T, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk).
BMJ
322
:
1
–6,
2001
28
Herman JB, Goldburt U: Uric acid and diabetes: observations in a population study.
Lancet
II
:
240
–244,
1982
29
Modan M, Halkin H, Karasik A, Lusky A: Elevated serum uric acid: a facet of hyperinsulinaemia.
Diabetologia
30
:
713
–718,
1987
30
Ames BN, Cathcart E, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.
Proc Natl Acad Sci U S A
78
:
6858
–6862,
1981
31
Becker BF: Towards the physiological function of uric acid.
Free Radic Biol Med
14
:
615
–631,
1993
32
Erdberg A, Boner G, Van Dyk DJ, Carel R: Urine uric acid excretion in patients with insulin-dependent diabetes mellitus.
Nephron
60
:
134
–137,
1992
33
Gonzalez-Sicilia L, Garcia-Estan J, Martinez-Blazquez A, Fernandez-Pardo J, Quiles JL, Hernandez J: Renal metabolism of uric acid in type 1 insulin-dependent diabetic patients: relation to metabolic compensation.
Horm Metab Res
29
:
520
–523,
1997
34
Cotroneo P, Manto A, Todaro L, Manto A Jr, Pitocco D, Saponara C, Vellante C, Maussier ML, D’Errico G, Magnani P: Hyperfiltration in patients with type 1 diabetes mellitus: a prevalence study.
Clin Nephrol
50
:
214
–217,
1998
35
Waring WS, Webb DJ, Maxwell SR: Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers.
J Cardiovasc Pharmacol
38
:
365
–371,
2001
36
Colhoun HM, Rubens MB, Underwood RS, Fuller JH: The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification.
J Am Coll Cardiol
36
:
2160
–2167,
2000
37
Valabhji J, McColl AJ, Richmond W, Schachter M, Rubens MB, Elkeles RS: Total antioxidant status and coronary artery calcification in type 1 diabetes.
Diabetes Care
24
:
1608
–1613,
2001
38
Brussard HE, Gevers Leuven AJ, Kluft C, Krans HMJ, van Duyvenvoorde W, Huytenhek R, van der Laarse A, Prince HMG: Effect of 17 β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus.
Arterioscler Throm Vasc Biol
17
:
324
–330,
1997
39
Cals MJ, Succari M, Meneguzzer E, Ponteziere C, Bories PN, Devanlay M, Desveaux N, Gatey M, Luciani L, Blonde-Cynober F, Coudray-Lucas C: Markers of oxidative stress in fit, health-conscious elderly people living in the Paris area: the Research Group on Ageing.
Nutrition
13
:
319
–326,
1997
40
Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GJ, Schnaper HW: Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells.
Circulation
94
:
1402
–1407,
1996
41
Lobo RA: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women.
J Clin Endocrinol Metab
73
:
925
–930,
1991
42
Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal oestrogen therapy and cardiovascular disease: ten year follow-up from the nurses’ health study.
N Engl J Med
325
:
756
–762,
1991
43
Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD: Type II diabetes abrogates gender differences in endothelial function in premenopausal women.
Circulation
101
:
2040
–2046,
2000
44
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med
117
:
1016
–1037,
1992
45
Gevers Leuven AJ: Sex steroids and lipoprotein metabolism.
Pharmacol Ther
64
:
99
–126,
1994
46
Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA: 17 β-Estradiol attenuates acetylcholine-induced coronary artery disease.
Circulation
92
:
24
–30,
1995

Address correspondence and reprint requests to Giovanni Ghirlanda, MD, Institute of Internal Medicine and Geriatry, Catholic University, L.go Gemelli 8, 00168, Rome, Italy. E-mail: gghirlanda@rm.unicatt.it.

Received for publication 12 April 2001 and accepted in revised form 24 October 2001.

P.C. is deceased.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.